Sign in

    Guyn Kim • Water Tower Research

    Do Kim is a Senior Research Analyst at Water Tower Research, focusing on the biotechnology and healthcare sectors with particular expertise in oncology, cell therapy, autoimmune, rare diseases, and antibody technology. He has joined Water Tower Research in 2024 to expand its healthcare coverage, leveraging a career that spans significant roles analyzing biotech and pharmaceutical companies across these domains. While detailed performance metrics and professional licensing information are not publicly disclosed, Kim brings a strong reputation for sector expertise and deep industry analysis to his position, building on years of specialized research experience. His professional background reflects advanced knowledge in both scientific developments and market trends shaping the biotech investment landscape.

    Guyn Kim's questions to Vivos Therapeutics Inc (VVOS) leadership

    Guyn Kim's questions to Vivos Therapeutics Inc (VVOS) leadership • Q3 2024

    Question

    Guyn Kim of Water Tower Research inquired about the early performance of the new sleep clinic marketing model, the strategy for integrating the pediatric population, and the company's projected path to achieving positive cash flow from operations.

    Answer

    CEO Kirk Huntsman expressed high confidence in the new model, citing strong patient interest with an 86% desire for further evaluation and over 50% proceeding with treatment. He explained that pediatric patient acquisition will leverage family connections of adult patients and direct marketing to schools and parent groups. CFO Brad Amman and CEO Kirk Huntsman clarified that achieving cash flow positivity is primarily dependent on revenue growth from the new, higher-margin model rather than further cost-cutting, with Huntsman estimating that approximately 250 patients per month under the new model could lead to breakeven.

    Ask Fintool Equity Research AI